DSM has entered an agreement to make an equity investment in Amyris.
The two companies will also develop products for the global health and nutrition markets (including vitamins and other nutritional ingredients).
Amyris’ technology supports DSM’s strategic markets in health, nutrition, and materials as well as a growing consumer shift to (bio-) natural-like products derived from sustainable sources.
For Amyris, DSM’s channels and market access and understanding in selecting the right products for the animal nutrition, human nutrition, and consumer health markets provide strategic value.
Equity investment
DSM will make an initial equity investment in Amyris of US$25 million, translating into a shareholding of about 12%.
Subject to the satisfaction of certain conditions, DSM may invest an additional US$25 million in Amyris.
As part of this investment, DSM will gain one board seat upon the closing of each tranche.
“Amyris has a unique yeast-based strain engineering platform that is very complementary to DSM’s capabilities in this area and will create great synergy with DSM’s know-how in fermentation, downstream process development and large-scale manufacturing,” said Chris Goppelsroeder, president and CEO of DSM Nutritional Products.
“Working closely together with Amyris and leveraging DSM’s route-to-market, will accelerate our innovation towards cost-effective, fermentation-based processes for both existing and new products.”
